Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 3
1950 1
1951 3
1952 4
1954 4
1955 1
1956 3
1958 3
1959 2
1960 3
1961 1
1962 2
1963 4
1964 2
1965 8
1966 11
1967 15
1968 13
1969 5
1970 7
1971 1
1972 5
1973 7
1974 13
1975 10
1976 19
1977 20
1978 17
1979 17
1980 23
1981 18
1982 20
1983 23
1984 25
1985 27
1986 25
1987 22
1988 23
1989 25
1990 25
1991 14
1992 17
1993 25
1994 28
1995 17
1996 30
1997 31
1998 22
1999 32
2000 30
2001 24
2002 25
2003 56
2004 40
2005 63
2006 55
2007 53
2008 47
2009 48
2010 67
2011 80
2012 84
2013 87
2014 108
2015 120
2016 122
2017 98
2018 81
2019 91
2020 122
2021 150
2022 136
2023 108
2024 97
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,431 results

Results by year

Filters applied: . Clear all
Page 1
Introduction to Hospice and Palliative Care.
Roth AR, Canedo AR. Roth AR, et al. Prim Care. 2019 Sep;46(3):287-302. doi: 10.1016/j.pop.2019.04.001. Epub 2019 Jun 13. Prim Care. 2019. PMID: 31375182 Review.
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Among authors: roth a. Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6. Lancet Haematol. 2016. PMID: 27132696 Clinical Trial.
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM, Chadwick JA, Owen RP, White MJ, Kaplinsky J, Peneva I, Frangou A, Xie PF, Chang J, Roth A, Amess B, James SA, Rei M, Fuchs HS, McCann KJ, Omiyale AO, Jacobs BA, Lord SR, Norris-Bulpitt S, Dobbie ST, Griffiths L, Ramirez KA, Ricciardi T, Macri MJ, Ryan A, Venhaus RR, Van den Eynde BJ, Karydis I, Schuster-Böckler B, Middleton MR, Lu X; LUD2015-005 Project Team. Carroll TM, et al. Among authors: roth a. Cancer Cell. 2023 Jul 10;41(7):1222-1241.e7. doi: 10.1016/j.ccell.2023.06.006. Cancer Cell. 2023. PMID: 37433281 Free article.
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, Röth A, Peffault de Latour R. Kulasekararaj AG, et al. Among authors: roth a. Blood. 2019 Feb 7;133(6):540-549. doi: 10.1182/blood-2018-09-876805. Epub 2018 Dec 3. Blood. 2019. PMID: 30510079 Free PMC article. Clinical Trial.
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socié G, Brodsky RA. Hillmen P, et al. Among authors: roth a. Br J Haematol. 2013 Jul;162(1):62-73. doi: 10.1111/bjh.12347. Epub 2013 Apr 25. Br J Haematol. 2013. PMID: 23617322 Free PMC article. Clinical Trial.
Acetaldehyde as a Food Flavoring Substance: Aspects of Risk Assessment.
Cartus AT, Lachenmeier DW, Guth S, Roth A, Baum M, Diel P, Eisenbrand G, Engeli B, Hellwig M, Humpf HU, Joost HG, Kulling SE, Lampen A, Marko D, Steinberg P, Wätjen W, Hengstler JG, Mally A. Cartus AT, et al. Among authors: roth a. Mol Nutr Food Res. 2023 Dec;67(23):e2200661. doi: 10.1002/mnfr.202200661. Epub 2023 Oct 15. Mol Nutr Food Res. 2023. PMID: 37840378 Review.
Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment.
Ma J, Al Moussawi K, Lou H, Chan HF, Wang Y, Chadwick J, Phetsouphanh C, Slee EA, Zhong S, Leissing TM, Roth A, Qin X, Chen S, Yin J, Ratnayaka I, Hu Y, Louphrasitthiphol P, Taylor L, Bettencourt PJG, Muers M, Greaves DR, McShane H, Goldin R, Soilleux EJ, Coleman ML, Ratcliffe PJ, Lu X. Ma J, et al. Among authors: roth a. Proc Natl Acad Sci U S A. 2024 Mar 5;121(10):e2309957121. doi: 10.1073/pnas.2309957121. Epub 2024 Feb 29. Proc Natl Acad Sci U S A. 2024. PMID: 38422022 Free PMC article.
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Röth A, et al. Blood. 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. Blood. 2022. PMID: 35687757 Free PMC article. Clinical Trial.
2,431 results